WaferGen Bio-systems, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Gain on revaluation of warrant derivative liabilities, net
Liquidated damages for late S-1 registration
Excess debt discount expensed as interest
Gain on settlement of derivative liability
Interest converted to principal on long-term debt
Provision for excess and obsolete inventory
Amortization of debt discount
Restricted cash
Loss on extinguishment of debt
Issuance of warrants due to organic change
Gain on liquidation of subsidiary
Deferred income taxes
Change in operating assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other assets
Accounts payable
Accrued payroll and related costs
Other accrued expenses
Net cash used in operating activities

Cash flows from investing activities:
Purchase of property and equipment
Acquisition of business
Cash of former subsidiary transferred to liquidator
Net cash used in investing activities
Net proceeds from issuance of Series 1 convertible preferred stock, common stock and warrants
Cash flows from financing activities:
Net proceeds from issuance of common stock and warrants (and Series 2 Convertible Preferred Stock in 2015 only)
Repayment of capital lease obligations
Repayment of promissory note
Purchase of Series B convertible preference shares of former subsidiary
Repayment of term loan
Net proceeds from issuance of Series A-1 convertible preferred stock, convertible promissory notes and warrants
Proceeds from issuance of common stock and warrants, net of offering costs
Payment of taxes for restricted stock forfeited
Net cash provided by financing activities

Effect of exchange rates on cash
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of the period
Cash and cash equivalents at end of the period
Cash paid for interest
Cash paid for income taxes
Cash (received) for income taxes
Supplemental disclosures of cash flow information:
Cash paid for interest
Cash paid for income taxes
Cash (received) for income taxes
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment acquired with capital leases
Warrant derivative liabilities transferred to equity on waiver of potential cash settlement provisions
Inventory transferred to property and equipment
Property and equipment transferred to inventory
Issuance of promissory note, net of debt discount, in business acquisition
Initial valuation of revenue earn-out contingency in business acquisition
Exchange of convertible promissory notes for common stock and Series 1 convertible preferred stock
Exchange of Series A-1 convertible preferred stock for common stock and Series 1 convertible preferred stock
Issuance of warrants classified as liabilities to placement agent
Accretion on Series 1 convertible preferred stock associated with beneficial conversion feature
Issuance of warrants to underwriters and placement agents
Accretion on Series 2 convertible preferred stock associated with beneficial conversion feature
Issuance of long-term debt, net of debt discount, upon liquidation of subsidiary
Extinguishment of Series C convertible preference shares upon liquidation of subsidiary

Comments